The responsibility of the pharmaceutical industry

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 6, 2001, Pages 2-4

  Durrant, C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ARTICLE; CHEMISTRY; DRUG INDUSTRY; ECONOMICS; GENOME; HUMAN; LEGAL ASPECT; RESEARCH; STANDARD;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; GENOME, HUMAN; HUMANS; OXAZOLIDINONES; RESEARCH;

EID: 0035749882     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00077.x     Document Type: Article

References (7)

1. Anonymous. Science and Profit. The Economist 2001; 358: 21-2.
2. Pharmaceutical Research and Manufacturers of America. New Medicines in Development for Infections Diseases. Washington DC: Pharmaceutical Research and Manufacturers of America, 2000.
3. Peterson LR, Gary A. Noskin, new technology for detecting multidrug-resistant pathogens in the clinical microbiology laboratory. Emerging Infectious Diseases 2001; 7: 306.
4. Pharmaceutical Research and Manufacturers of America. Leading the Way in Search for Cures. Washington DC: Pharmaceutical Research and Manufacturers of America, 2000.
5. Anonymous. The Line of Least Resistance. The Economist 2001; 359: 71-2.
6. Kollef MH. Inadequate antimicrobial treatment. An important determinant of outcomes for hospitalized patients. Clin Infectious Dis 2000; 31 (Suppl. 4): S131-8.
7. Charan R. Conquering a Culture of Indecision. Harvard Business Review 2001; 79 (4): 80.